Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Cash & Equivalents (2016 - 2025)

Medifast (MED) has disclosed Cash & Equivalents for 15 consecutive years, with $90.9 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Cash & Equivalents changed N/A year-over-year to $90.9 million, compared with a TTM value of $90.9 million through Dec 2024, changed N/A, and an annual FY2024 reading of $90.9 million, changed N/A over the prior year.
  • Cash & Equivalents was $90.9 million for Q4 2024 at Medifast, down from $97.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $206.0 million in Q1 2021 and bottomed at $69.7 million in Q3 2022.
  • Average Cash & Equivalents over 5 years is $128.9 million, with a median of $123.7 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents surged 127.23% in 2021, then crashed 54.88% in 2022.
  • Year by year, Cash & Equivalents stood at $163.7 million in 2020, then tumbled by 36.37% to $104.2 million in 2021, then fell by 15.83% to $87.7 million in 2022, then surged by 68.1% to $147.4 million in 2023, then tumbled by 38.31% to $90.9 million in 2024.
  • Business Quant data shows Cash & Equivalents for MED at $90.9 million in Q4 2024, $97.5 million in Q1 2024, and $147.4 million in Q2 2023.